



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Service
Prior Authorization Criteria

ANORO ELLIPTA[®] (umeclidinium-vilanterol inhalation powder)
[Prior Authorization Request Form](#)

ANORO ELLIPTA is a combination of umeclidinium, a long-acting anticholinergic, and vilanterol, a long-acting beta 2-adrenergic agonist (LABA). Anoro Ellipta is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). *Anoro Ellipta is not indicated for the treatment of asthma.*

Prior authorization requests for Anoro Ellipta will be approved if the following criteria are met:

- 1) Patient must be eighteen (18) years of age or older; **AND**
- 2) Patient must have had a diagnosis of COPD; **AND**
- 3) Patient must have had a thirty (30) day trial of a LABA or a combination drug containing a LABA; **AND**
- 4) Patient must have had a **concurrent thirty** (30) day trial with a long-acting anticholinergic; **AND**
- 5) Prior-authorization will be denied for patients with a sole diagnosis of asthma.

References

2014 GOLD guidelines: (http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdf)
Anoro Ellipta package insert 05/2014
Lexi-Comp Clinical Application September 2014
Detail-Document; Pharmacist's Letter 2014; 30(4):300403

Review and Approved
DUR Board 09/17/2014